Post-Market Requirements Could Broaden Label For Allos' Newly Approved PTCL Drug Folotyn
This article was originally published in The Pink Sheet Daily
Executive Summary
Allos gains its first U.S. indication with the accelerated approval of Folotyn (pralatrexate) in peripheral T-cell lymphoma.